Q2 2026 saw 5.6% operational sales growth to $25.3B, with double-digit growth excluding STELARA. Full-year guidance was raised, driven by strong Innovative Medicine and MedTech launches, robust pipeline progress, and strategic acquisitions.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.